William Blair & Company
DFTX

William Blair & Company’s Definium Therapeutics DFTX Stock Holding History

William Blair & Company’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.01M Buy
+53,695
New +$911K ﹤0.01% 938
2025
Q4 		– Sell
-31,905
Closed -$376K – 1918
2025
Q3 		$376K Buy
31,905
+9,687
+44% +$90.3K ﹤0.01% 1215
2025
Q2 		$144K Buy
22,218
+9,718
+78% +$63.9K ﹤0.01% 1470
2025
Q1 		$73.1K Buy
+12,500
New +$89.5K ﹤0.01% 1543
2024
Q4 		– Sell
-11,000
Closed -$62.6K – 1858
2024
Q3 		$62.6K Sell
11,000
-268
-2% -$1.86K ﹤0.01% 1604
2024
Q2 		$81.2K Sell
11,268
-73
-0.6% -$638 ﹤0.01% 1537
2024
Q1 		$107K Buy
+11,341
New +$64.7K ﹤0.01% 1497
2021
Q4 		– Sell
-885
Closed -$32K – 2003
2021
Q3 		$32K Sell
885
-177
-17% -$7.65K ﹤0.01% 1726
2021
Q2 		$55K Buy
+1,062
New +$55.7K ﹤0.01% 1681

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

William Blair & Company's DFTX Position: Q1 2026 in Review

William Blair & Company opened a new position in Definium Therapeutics (DFTX) in Q1 2026: 53,695 shares worth $1.01M. The stake represents ﹤0.01% of the portfolio and ranks #938 among its holdings. This is a return to the name: William Blair & Company previously reported a position in DFTX as recently as Q3 2025.

William Blair & Company first reported a position in DFTX in Q2 2021 and has held it in 9 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • William Blair & Company held 53,695 shares of Definium Therapeutics worth $1.01M as of Q1 2026.
  • Definium Therapeutics was a new William Blair & Company position in Q1 2026.
  • Definium Therapeutics made up ﹤0.01% of William Blair & Company's portfolio in Q1 2026, its #938 holding.
  • William Blair & Company first reported a position in Definium Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.